Pfizer, BioNTech request expanded emergency use of COVID-19 vaccine in adolescents
Pfizer, BioNTech request expanded emergency use of COVID-19 vaccine in adolescents
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
(Reporting by Mrinalika Roy in Bengaluru; Editing by
Ramakrishnan M.)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;)
April 9 (Reuters) - Pfizer Inc and german partner BioNtech SE on Friday said they have requested U.S. regulatory agencies to expand the emergency use of their COVID-19 vaccine in adolescents aged 12 to 15.
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
(Reporting by Mrinalika Roy in Bengaluru; Editing by
Ramakrishnan M.)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;)
路透4月9日电-辉瑞(Pfizer Inc.)和德国合作伙伴BioNTech SE周五表示，他们已要求美国监管机构扩大其新冠肺炎疫苗的紧急使用范围，适用于12至15岁的青少年。今年3月，制药商表示，在一项临床试验中，该疫苗被发现是安全、有效的，并在12至15岁的儿童中产生了强大的抗体反应。辉瑞/BioNTech双针疫苗已经获准在16岁以下的人群中使用。(Mrinalika Roy在孟加卢市报道；编辑者：Ramakrishnan M.)(mrinalika.roy@thomsonreurs.com；在美国境内+1 646 2238780，美国境外+91 806749 8325；)
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧